4 completed, 1 unknown. 3 Phase 3, 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Unknown 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow HBM9161: new trials by email Literature Review of HBM9161 trials Research Report on HBM9161
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis HBM9161 Injection (680mg) - Myasthenia Gravis | Phase 3 | Completed | Harbour BioMed (Guangzhou) Co. Ltd. | 111 | 2022-06-30 | 2026-04-28 |
| Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients HBM9161 Injection (680mg), Placebo - Myasthenia Gravis | Phase 3 | Completed | Harbour BioMed (Guangzhou) Co. Ltd. | 132 | 2021-09-25 | 2023-03-08 |
| A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease HBM9161 680 mg qw by q2w from week 13, Placebo, HBM9161 680 mg qw by q2w from week 7 - Thyroid Ophthalmopathy | Phase 2 / Phase 3 | Unknown | Harbour BioMed (Guangzhou) Co. Ltd. | 36 | 2021-09-22 | 2022-02-23 |
| A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients HBM9161 Injection (680mg and 340 mg), Placebos, HBM9161 Injection (340 mg) - Myasthenia Gravis | Phase 2 | Completed | Harbour BioMed (Guangzhou) Co. Ltd. | 30 | 2020-07-23 | 2023-03-08 |
| A Study of HBM9161 in NMOSD Patients HBM9161 Injection - NMO Spectrum Disorder | Phase 1 | Completed | Harbour BioMed (Guangzhou) Co. Ltd. | 9 | 2020-03-31 | 2022-01-25 |
Myasthenia Gravis (3) · Graves Ophthalmopathy (1) · Neuromyelitis Optica (1)
Harbour BioMed (Guangzhou) Co. Ltd. (5)
China (5)
Chongbo Zhao (2) · Huifang Zhou (1) · Wei Qiu (1)